Xian Ming 4

What Happened

• Xian Ming, a director of Medifast, received an award of 11,680 restricted stock units (RSUs) on May 26, 2026. The Form 4 records the grant as a derivative acquisition at $0.00 (the filing reports $0 because these RSUs are a contingent right rather than an immediate share transfer). The RSUs will vest in full on May 26, 2027 and each unit represents a contingent right to receive the cash equivalent of one share of Medifast common stock at vesting.

Key Details

• Transaction date: 2026-05-26; Form 4 filed: 2026-05-28 (filed two days after the transaction, which appears timely).
• Transaction type/code: A (award/grant); amount: 11,680 RSUs; price in filing: $0.00 (derivative).
• Shares owned after transaction: not specified in the filing.
• Footnote: These RSUs are an annual grant under the 2012 Share Incentive Plan and are cash‑settled on the vesting date (May 26, 2027).
• No indication of a 10b5‑1 plan, tax‑withholding sale, or other special sale/transfer in this filing.

Context

• RSU grants are a common form of compensation and are not direct purchases or sales of stock; because these are cash‑settled, Xian will receive the cash value of shares at vesting rather than shares themselves.
• Awards like this are routine for executives and directors and do not necessarily signal an insider view on near‑term stock performance.